The dopamine dysfunction in schizophrenia revisited: new insights into topography and course.

Schizophrenia has long been associated with an imbalance in dopamine (DA) neurotransmission, and brain imaging has played an important role in advancing our knowledge and providing evidence for the dopaminergic abnormalities. This chapter reviews the evidence for DA dysfunction in different brain regions in schizophrenia, in particular striatal, extrastriatal, and prefrontal regions, with emphasis on recently published findings. As opposed to the traditional view that most striatal dopaminergic excess, associated with the positive symptoms of schizophrenia, involves the dopaminergic mesolimbic pathway, recent evidence points to the nigrostriatal pathway as the area of highest dysregulation. Furthermore, evidence from translational research suggests that dopaminergic excess may be present in the prodromal phase, and may by itself, as suggested by the phenotype observed in transgenic mice with developmental overexpression of dorso-striatal D(2) receptors, be an early pathogenic condition, leading to irreversible cortical dysfunction.

[1]  H. Moore,et al.  Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. , 2009, Archives of general psychiatry.

[2]  Tomiki Sumiyoshi,et al.  Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression , 1995, Brain Research.

[3]  Samuel M. McClure,et al.  BOLD Responses Reflecting Dopaminergic Signals in the Human Ventral Tegmental Area , 2008, Science.

[4]  M. Laruelle Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[5]  D. Sibley,et al.  Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. , 1982, The Journal of biological chemistry.

[6]  M. Laakso,et al.  Midbrain dopamine D2/3 receptor binding in schizophrenia , 2006, European Archives of Psychiatry and Clinical Neuroscience.

[7]  A. Arnsten,et al.  Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. , 2007, Cerebral cortex.

[8]  M. Laruelle,et al.  Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.

[9]  R. V. Van Heertum,et al.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M Laruelle,et al.  Stability of [123I]IBZM SPECT measurement of amphetamine‐induced striatal dopamine release in humans , 1999, Synapse.

[11]  J. Lisman Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia? , 2012, Current Opinion in Neurobiology.

[12]  Tyrone D. Cannon,et al.  Brain dopamine d1 receptors in twins discordant for schizophrenia. , 2006, The American journal of psychiatry.

[13]  D. Doudet,et al.  6-18F-DOPA PET study in patients with schizophrenia , 2000, Psychiatry Research: Neuroimaging.

[14]  G. Firnau,et al.  [18F]Fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine , 1978 .

[15]  P Riederer,et al.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[16]  A. Grace,et al.  Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia , 2008, Neurotoxicity Research.

[17]  T. McGlashan,et al.  Striatal Dopamine Synthesis in First-degree Relatives of Patients with Schizophrenia , 2008, Biological Psychiatry.

[18]  Harumasa Takano,et al.  Regional dopamine synthesis in patients with schizophrenia using L-[β-11C]DOPA PET , 2009, Schizophrenia Research.

[19]  M. Laruelle,et al.  Striatal and Extrastriatal Dopamine D2/D3 Receptors in Schizophrenia Evaluated With [18F]fallypride Positron Emission Tomography , 2010, Biological Psychiatry.

[20]  Christer Halldin,et al.  Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography , 2006, Psychiatry Research: Neuroimaging.

[21]  Patricia S. Goldman-Rakic,et al.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction , 2004, Psychopharmacology.

[22]  S. Otsuki,et al.  Effects of intermittent and continuous haloperidol administration on the dopaminergic system in the rat brain , 1986, Biological Psychiatry.

[23]  R. V. Van Heertum,et al.  Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.

[24]  J. M. Ollinger,et al.  Positron Emission Tomography , 2018, Handbook of Small Animal Imaging.

[25]  P. McGuire,et al.  Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. , 2010, Archives of general psychiatry.

[26]  M. Laruelle Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[28]  T. Crow,et al.  3H-flupenthixol binding in post-mortem brains of schizophrenics: Evidence for a selective increase in dopamine D2 receptors , 2004, Psychopharmacology.

[29]  J. Hietala,et al.  Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. , 2000, The American journal of psychiatry.

[30]  K. Berridge,et al.  What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? , 1998, Brain Research Reviews.

[31]  R. Narendran,et al.  Increased prefrontal cortical D1 receptors in drug naïve patients with schizophrenia: a PET study with [11C]NNC112 , 2012, Journal of psychopharmacology.

[32]  A. Deutch The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. , 1992, Journal of neural transmission. Supplementum.

[33]  Gary Remington,et al.  Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient , 2001, Biological Psychiatry.

[34]  Christer Halldin,et al.  Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain , 1994, Neuropsychopharmacology.

[35]  A Carlsson,et al.  Antipsychotic drugs, neurotransmitters, and schizophrenia. , 1978, The American journal of psychiatry.

[36]  A. Gjedde,et al.  Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms , 1998, Synapse.

[37]  L. Siever,et al.  Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide , 2004, Biological Psychiatry.

[38]  H. Möller,et al.  The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1 , 2005, Journal of psychopharmacology.

[39]  Kun-Ju Lin,et al.  Dopamine transporter change in drug-naı̈ve schizophrenia: an imaging study with 99mTc-TRODAT-1 , 2003, Schizophrenia Research.

[40]  Minda R. Lynch,et al.  Schizophrenia and the D1 receptor: Focus on negative symptoms , 1992, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[41]  P. Seeman All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors , 2011, CNS neuroscience & therapeutics.

[42]  Sylvain Houle,et al.  High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [11C]-(+)-PHNO , 2006, Biological Psychiatry.

[43]  S. Kapur,et al.  Dopamine, prediction error and associative learning: A model-based account , 2006, Network.

[44]  J. Krystal,et al.  Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT , 2000, Biological Psychiatry.

[45]  E. Kandel,et al.  Transient Overexpression of Striatal D2 Receptors Impairs Operant Motivation and Interval Timing , 2007, The Journal of Neuroscience.

[46]  D. Weinberger Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[47]  M Laruelle,et al.  Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. , 1998, The American journal of psychiatry.

[48]  Harumasa Takano,et al.  Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. , 2009, Journal of psychiatric research.

[49]  R. Conley,et al.  Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study , 1998, Molecular Psychiatry.

[50]  A. Carlsson Does dopamine play a role in schizophrenia? , 1977, Psychological Medicine.

[51]  R. Gur,et al.  Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. , 1997, Archives of general psychiatry.

[52]  Gavin P. Reynolds,et al.  A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia , 2002, Schizophrenia Research.

[53]  P. McGuire,et al.  Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis , 2011, Molecular Psychiatry.

[54]  E. Fernandez-Egea,et al.  Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait , 2007, Psychopharmacology.

[55]  David A Lewis,et al.  Intrinsic excitatory connections in the prefrontal cortex and the pathophysiology of schizophrenia , 2000, Brain Research Bulletin.

[56]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Sohee Park,et al.  Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions. , 2011, The American journal of psychiatry.

[58]  S. Kapur,et al.  The dopamine hypothesis of schizophrenia: version III--the final common pathway. , 2009, Schizophrenia bulletin.

[59]  Alain Dagher,et al.  Stress-Induced Dopamine Release in Humans at Risk of Psychosis: a [11C]Raclopride PET Study , 2008, Neuropsychopharmacology.

[60]  S. Kapur,et al.  Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels , 2000, Psychopharmacology.

[61]  D. Copolov,et al.  The Binding of Both [3H]Nemonapride and [3H]Raclopride Is Increased in Schizophrenia , 1997, Biological Psychiatry.

[62]  S. Kapur,et al.  The Formation of Abnormal Associations in Schizophrenia: Neural and Behavioral Evidence , 2008, Neuropsychopharmacology.

[63]  C. Nahmias,et al.  Dopamine visualized in the basal ganglia of living man , 1983, Nature.

[64]  B. Dawant,et al.  Dopamine D2 Receptor Levels in Striatum, Thalamus, Substantia Nigra, Limbic Regions, and Cortex in Schizophrenic Subjects , 2009, Biological Psychiatry.

[65]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[66]  J. Hietala,et al.  Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.

[67]  R. Conley,et al.  D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. , 1996, Neuroreport.

[68]  G. Reynolds,et al.  [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. , 1985, European journal of pharmacology.

[69]  M. Hallett,et al.  Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA , 2008, Psychiatry Research: Neuroimaging.

[70]  D. Javitt,et al.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia , 2008, Trends in Neurosciences.

[71]  Alan A. Wilson,et al.  Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study , 2000, Psychopharmacology.

[72]  G. Reynolds,et al.  Are Striatal Dopamine D4 Receptors Increased in Schizophrenia? , 1994, Journal of neurochemistry.

[73]  Mark Slifstein,et al.  In Vivo DA D1 Receptor Selectivity of NNC 112 and SCH 23390 , 2007, Molecular Imaging and Biology.

[74]  T. Hyde,et al.  Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[75]  M. Bergström,et al.  Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(β-11C) DOPA and PET , 1999, Biological Psychiatry.

[76]  S. Haber,et al.  Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. , 2010, Archives of general psychiatry.

[77]  R. V. Van Heertum,et al.  NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans , 2002, Synapse.

[78]  Anissa Abi-Dargham,et al.  Do we still believe in the dopamine hypothesis? New data bring new evidence. , 2004, The international journal of neuropsychopharmacology.

[79]  D. Linszen,et al.  Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT , 2001, Schizophrenia Research.

[80]  Bradley T. Christian,et al.  D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia , 2006, Schizophrenia Research.

[81]  Alan A. Wilson,et al.  In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]‐(+)‐PHNO in rats using an intracerebral beta‐sensitive system , 2006, Synapse.

[82]  Status of the dopaminergic system in post-mortem brain in schizophrenia. , 1988, Psychopharmacology bulletin.

[83]  A. Grace,et al.  The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. , 1995, Drug and alcohol dependence.

[84]  A. Meyer-Lindenberg,et al.  Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia , 2002, Nature Neuroscience.

[85]  P. Seeman,et al.  Dopamine D4 receptors elevated in schizophrenia , 1993, Nature.

[86]  Tyrone D. Cannon,et al.  Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. , 2005, Archives of general psychiatry.

[87]  Johannes Schwarz,et al.  Psychosis pathways converge via D2High dopamine receptors , 2006, Synapse.

[88]  Mark Slifstein,et al.  Altered prefrontal dopaminergic function in chronic recreational ketamine users. , 2005, The American journal of psychiatry.

[89]  M. Laruelle,et al.  Glutamate, Dopamine, and Schizophrenia , 2003 .

[90]  Andrew D. Roberts,et al.  FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa , 1999, Neurology.

[91]  Van Rossum Jm The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. , 1966 .

[92]  Ryan D Ward,et al.  Impaired timing precision produced by striatal D2 receptor overexpression is mediated by cognitive and motivational deficits. , 2009, Behavioral neuroscience.

[93]  C. Crouzel,et al.  Presynaptic dopaminergic function in the striatum of schizophrenic patients , 1997, Schizophrenia Research.

[94]  R. Murray,et al.  Striatal dopamine synthesis capacity in twins discordant for schizophrenia , 2011, Psychological Medicine.

[95]  P. Goldman-Rakic,et al.  Functional and anatomical aspects of prefrontal pathology in schizophrenia. , 1997, Schizophrenia bulletin.

[96]  S. Kapur,et al.  From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis , 2005, Schizophrenia Research.

[97]  E. Walker,et al.  Dopamine receptors in the brains of schizophrenia patients: a meta‐analysis of the findings , 2001, Behavioural pharmacology.

[98]  J. Pavía,et al.  Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism , 2005, Psychopharmacology.

[99]  Henrik Walter,et al.  Prediction error as a linear function of reward probability is coded in human nucleus accumbens , 2006, NeuroImage.

[100]  Arno Villringer,et al.  Dysfunction of ventral striatal reward prediction in schizophrenia , 2006, NeuroImage.

[101]  J. Kleinman,et al.  Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients , 1994, Biological Psychiatry.

[102]  Kevin T. Hansen,et al.  Dopamine D2 densities and the schizophrenic brain , 1998, Schizophrenia Research.

[103]  M. Laruelle,et al.  [11C]NNC 112 Selectivity for Dopamine D1 and Serotonin 5-HT2A Receptors: A PET Study in Healthy Human Subjects , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[104]  Marc Laruelle,et al.  Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.

[105]  W. Schultz Predictive reward signal of dopamine neurons. , 1998, Journal of neurophysiology.

[106]  Nikolaos Koutsouleris,et al.  Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug–naive schizophrenic patients , 2006, European Archives of Psychiatry and Clinical Neuroscience.

[107]  J. Hietala,et al.  Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia , 1999, Schizophrenia Research.

[108]  J. Tiihonen,et al.  Extrastriatal dopamine D2/3 receptor density and distribution in drug-naive schizophrenic patients , 2003, Molecular Psychiatry.

[109]  A. Meyer-Lindenberg,et al.  Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. , 2005, Archives of general psychiatry.

[110]  Paul J. Harrison The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications , 2004, Psychopharmacology.

[111]  M. Laruelle,et al.  Baseline and Amphetamine-Stimulated Dopamine Activity Are Related in Drug-Naïve Schizophrenic Subjects , 2009, Biological Psychiatry.

[112]  J. Kleinman,et al.  Dopamine receptor subtype imbalance in schizophrenia. , 1987, Life sciences.

[113]  E. Kandel,et al.  Transient and Selective Overexpression of Dopamine D2 Receptors in the Striatum Causes Persistent Abnormalities in Prefrontal Cortex Functioning , 2006, Neuron.

[114]  D. Erritzoe,et al.  Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. , 2003, Neuroimaging clinics of North America.

[115]  M. Cannon,et al.  Psychotic-like experiences in the general population: characterizing a high-risk group for psychosis , 2010, Psychological Medicine.

[116]  A. Grace,et al.  Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission , 2003, Nature Neuroscience.

[117]  Sylvain Houle,et al.  Binding characteristics and sensitivity to endogenous dopamine of [11C]‐(+)‐PHNO, a new agonist radiotracer for imaging the high‐affinity state of D2 receptors in vivo using positron emission tomography , 2006, Journal of neurochemistry.

[118]  R. Murray,et al.  Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study , 2011, Molecular Psychiatry.

[119]  P. Glimcher,et al.  Midbrain Dopamine Neurons Encode a Quantitative Reward Prediction Error Signal , 2005, Neuron.

[120]  P. Sokoloff,et al.  The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches , 1995, European Neuropsychopharmacology.

[121]  E. Bézard,et al.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. , 2006, CNS & neurological disorders drug targets.

[122]  Marie-Claude Asselin,et al.  Elevated striatal dopamine function linked to prodromal signs of schizophrenia. , 2009, Archives of general psychiatry.

[123]  Jeffrey A Lieberman,et al.  Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity , 1997, Neuropsychopharmacology.

[124]  Eleanor H. Simpson,et al.  A Possible Role for the Striatum in the Pathogenesis of the Cognitive Symptoms of Schizophrenia , 2010, Neuron.

[125]  C. Halldin,et al.  Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. , 2003, The international journal of neuropsychopharmacology.

[126]  P Seeman,et al.  Dopamine D2 receptors mapped in rat brain with [3H](+)PHNO , 1994, Synapse.

[127]  G. Sedvall,et al.  PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. , 2002, The American journal of psychiatry.

[128]  A. Arnsten Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia , 2011, International Journal of Developmental Neuroscience.

[129]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[130]  P. Chen,et al.  Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. , 2004, The American journal of psychiatry.

[131]  A. Grace,et al.  The Yin and Yang of dopamine release: a new perspective , 2007, Neuropharmacology.

[132]  R. Mizrahi Advances in PET analyses of stress and dopamine , 2010, Neuropsychopharmacology.

[133]  Alan A. Wilson,et al.  D2-Receptor Upregulation is Dependent upon Temporal Course of D2-Occupancy: A Longitudinal [11C]-Raclopride PET Study in Cats , 2009, Neuropsychopharmacology.

[134]  D. Weinberger,et al.  Dopamine, the prefrontal cortex and schizophrenia , 1997, Journal of psychopharmacology.

[135]  F. Yasuno,et al.  Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. , 2004, The American journal of psychiatry.

[136]  S. Tanada,et al.  Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. , 2002, Archives of general psychiatry.

[137]  Ariel Graff-Guerrero,et al.  The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study , 2009, Neuropsychopharmacology.

[138]  R. Dolan,et al.  Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans , 2006, Nature.

[139]  A. Grace Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia , 1991, Neuroscience.

[140]  P S Goldman-Rakic,et al.  The “Psychic” Neuron of the Cerebral Cortex , 1999, Annals of the New York Academy of Sciences.

[141]  A. Grace,et al.  The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes , 2004, Neuropsychopharmacology.

[142]  Philip Seeman,et al.  Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[143]  Alan C. Evans,et al.  Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[144]  R. Joosten,et al.  Reward-Predictive Cues Enhance Excitatory Synaptic Strength onto Midbrain Dopamine Neurons , 2008, Science.

[145]  Karmen K. Yoder,et al.  Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia , 2004, Schizophrenia Research.

[146]  Ariel Graff-Guerrero,et al.  Brain region binding of the D2/3 agonist [11C]‐(+)‐PHNO and the D2/3 antagonist [11C]raclopride in healthy humans , 2008, Human brain mapping.

[147]  E. Bird,et al.  Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia , 1988, Synapse.

[148]  J. Pierri,et al.  Decreased density of tyrosine hydroxylase–immunoreactive axons in the entorhinal cortex of schizophrenic subjects , 2000, Biological Psychiatry.

[149]  C. Svarer,et al.  Frontal Dopamine D2/3 Receptor Binding in Drug-Naive First-Episode Schizophrenic Patients Correlates with Positive Psychotic Symptoms and Gender , 2006, Biological Psychiatry.

[150]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[151]  Marc Laruelle,et al.  Dopamine Depletion and In Vivo Binding of PET D1 Receptor Radioligands: Implications for Imaging Studies in Schizophrenia , 2003, Neuropsychopharmacology.

[152]  D. Charney,et al.  Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release , 1995, Schizophrenia Research.

[153]  R. Murray,et al.  Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. , 2011, The American journal of psychiatry.

[154]  A. Lawrence,et al.  Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. , 2004, Archives of general psychiatry.

[155]  S. Snyder,et al.  Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. , 1977, Science.

[156]  S H Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.

[157]  Merja Haaparanta,et al.  Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia , 2001, Schizophrenia Research.

[158]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[159]  Anthony A. Grace,et al.  Dopamine system dysregulation by the hippocampus: Implications for the pathophysiology and treatment of schizophrenia , 2012, Neuropharmacology.

[160]  Bita Moghaddam,et al.  Bringing Order to the Glutamate Chaos in Schizophrenia , 2003, Neuron.

[161]  M. Iyo,et al.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.

[162]  S. Kapur,et al.  Half a century of antipsychotics and still a central role for dopamine D2 receptors , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[163]  H. Möller,et al.  Dual-isotope SPECT imaging of striatal dopamine: First episode, drug naïve schizophrenic patients , 2008, Schizophrenia Research.